Open AccessP1219: ZANUBRUTINIB, LENALIDOMIDE PLUS R‐CHOP (ZR2‐CHOP) AS THE FIRST‐LINE TREATMENT FOR NON‐GCB DIFFUSED LARGE B‐CELL LYMPHOMA (DLBCL)
Author(s) -
Zhu H.,
Sha Y.,
Miao Y.,
Qin S.,
Wu W.,
Qiu J.,
Mi H.,
Yang Y.,
Peng C.,
Ding C.,
Wang Z.,
Fan L.,
Xu W.,
Li J.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000847740.08829.48
Subject(s) - medicine , lenalidomide , vincristine , rituximab , chop , diffuse large b cell lymphoma , oncology , clinical endpoint , lymphoma , surgery , gastroenterology , cyclophosphamide , chemotherapy , clinical trial , multiple myeloma